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The infection mechanism of vaccinia virus is largely unknown. Neither the attachment protein of extracellular enveloped
virus (EEV), the biologically relevant infectious form of the virus, nor its cellular receptor has been identified. Surprisingly, all
former attempts using antibodies to block EEV infection of cells in vitro had failed. Here, we report the production of an
anti-envelope hyperimmune serum with EEV neutralizing activity and show that a polyclonal antiserum against the extraviral
domain of protein B5R also inhibited EEV infection. In vivo, mice vaccinated with B5R protein were protected against a lethal
vaccinia virus challenge. This protectivity is likely to be mediated by neutralizing antibodies. Protein A33R, but not A34R and
A36R, also proved to be protective in active and passive vaccination experiments. However, in contrast to B5R, A33R
protectivity did not correlate with antibody titers. Because anti-A33R antibodies did not neutralize EEV in vitro, the protectivity
mediated by A33R protein probably involves a mechanism different from simple antibody binding. Taken together, our results
suggest that antibodies to a specific protective epitope or epitopes on protein B5R are able to prevent EEV infection. The
protein encoded by the B5R gene is therefore likely to play a crucial role in the initial steps of vaccinia virus infection—
binding to a host cell and entry into its cytoplasm. © 1999 Academic Press
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AINTRODUCTION
Vaccinia virus (V V) is a large complex DNA virus of the
oxviridae family. It replicates in the cytoplasm, and its
enome encodes ;200 proteins (Goebel et al., 1990).
wo major infectious forms of VV have been described:
ntracellular mature virus (IMV) and extracellular envel-
ped virus (EEV) (Appleyard et al., 1971; Ichihashi et al.,
971; Payne, 1980). IMV is the major form that remains in
he cytoplasm. It is composed of two tightly opposed
embranes (Sodeik et al., 1993) but can acquire two
dditional membranes derived from the trans-Golgi cis-
ernae (Hiller and Weber, 1985; Schmelz et al., 1994;
ooze et al., 1993). The resulting intracellular enveloped
irus (IEV) is transported by actin-containing microfila-
ents to the periphery of the cell (Cudmore et al., 1995;
iller et al., 1981; Stokes 1976), where their outermost
embrane fuses with the plasma membrane. These par-
icles may remain attached to the cell surface as cell-
ssociated enveloped virus (CEV) or may be released as
EV (Blasco and Moss, 1992; Ichihashi et al., 1971; Mor-
an, 1976; Payne, 1979; Schmelz et al., 1994). Even if
EVs represent a minor fraction of infectious particles, it
s the biologically relevant form in terms of long-range
issemination of virus in vitro and in vivo (Payne, 1980). It
as been well documented that immune responses
1 To whom reprint requests should be addressed. Fax: 141-21-692-
1-15. E-mail: riccardo.wittek@iba.unil.ch.
2 Present address: Laboratory of Polymers and Biomaterials, Depart-
ent of Chemistry, Swiss Federal Institute of Technology, 1015 Lau-banne, Switzerland.
71gainst EEV, and not against IMV, confer protection
gainst orthopoxvirus infection (Appleyard et al., 1971;
oulter, 1969; Boulter and Appleyard, 1973; Boulter et al.,
971; Morgan, 1976; Payne, 1980; Payne and Kristensson,
985; Turner and Squires, 1971).
Six genes are known to encode proteins present in the
EV outer envelope: A33R, encoding 23K—28K glyco-
roteins gp23-28 (Roper et al., 1996); A34R, encoding
p22-24 (Duncan and Smith, 1992); A36R, encoding
45-50 (Parkinson and Smith, 1994); A56R encoding the
emagglutinin gp86 (Payne and Norrby, 1976; Shida,
986); B5R, encoding gp42 (Engelstad et al., 1992; Isaacs
t al., 1992); and F13L, encoding a nonglycosylated 37K
rotein (Blasco and Moss, 1991; Hirt et al., 1986). Except
or the hemagglutinin, interference with the expression of
ny of these proteins by deletion or repression was
hown to have a dramatic impact on the ability of the
irus to spread from cell to cell in tissue culture and to
orm plaques (Blasco and Moss, 1991; Duncan and
mith, 1992; Engelstad and Smith, 1993; Herrera et al.,
998; Mathew et al., 1998; McIntosh and Smith, 1996;
oper et al., 1988; Seki et al., 1990; Wolffe et al., 1993).
owever, modifications of these proteins seemed to
ave different consequences on EEV production and
irulence (Smith, 1993). For example, the small plaque
henotype observed with F13L and B5R deletion mutants
as probably due to a drastic decrease in EEV formation
Blasco and Moss, 1991; Engelstad and Smith, 1993;
olffe et al., 1993). However, deletion of the A34R or the
33R genes also resulted in a small plaque phenotype
ut in an increase in EEV formation (McIntosh and Smith,
0042-6822/99 $30.00
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72 GALMICHE ET AL.996; Roper et al., 1998; Wolffe et al., 1997). Deletion of
he hemagglutinin gene does not affect plaque size but
ather causes the formation of syncytia (Ichihashi et al.,
971; Shida and Dales, 1982). Modification of the genes
ere also shown to attenuate the virus in vivo (Blasco
nd Moss, 1991; Engelstad and Smith, 1993; McIntosh
nd Smith, 1996; Parkinson and Smith, 1994; Wolffe et al.,
993). Even if these experiments demonstrated the im-
ortance of EEV-specific proteins, still very little is known
bout their involvement in EEV formation and egress
rom the infected cell, as well as their roles in attachment
o the cell surface, entry, and uncoating.
In 1996, Ichihashi (1996) suggested that EEV entry
nvolved binding to the host cell followed by endocytosis.
isruption of the EEV outer membrane would then allow
he IMV form to fuse with the endosomal membrane and
o release the viral core into the cytoplasm (Ichihashi,
996). This hypothesis has recently been supported by
he work of Vanderplasschen et al. (1998). The model
mplies that antibodies recognizing a specific cell attach-
ent protein or proteins on the EEV should be able to
nterfere with the first step in infection, that is, binding to
he host cell. Surprisingly, all attempts to identify antibod-
es that inhibit infection with EEV had failed so far (Ichi-
ashi, 1996; Vanderplasschen et al., 1997).
In contrast to these previous findings, we produced an
ntiserum against EEV envelope proteins (a-VV-env.),
hich was able to neutralize EEV in vitro. Based on this
esult, we wanted to see whether it was possible to
nhibit EEV infection with antibodies against individual
EV proteins. Disruption or modification of the hemag-
lutinin did not affect EEV production and infectivity (Gal-
iche et al., 1997; Ichihashi and Dales, 1971), and the
13L gene product p37 is not exposed on the EEV sur-
ace but lines the inner side of the envelope (Schmutz et
l., 1995). We therefore tested the four remaining enve-
ope proteins encoded by the genes A33R, A34R, A36R,
nd B5R for their ability to induce antibodies neutralizing
EV in vitro and to confer protection against a vaccinia
irus challenge in vivo.
RESULTS
Anti-EEV envelope protein antibodies are able to neu-
ralize EEV infection in vitro. EEV is an IMV particle with
n envelope containing a specific set of proteins. A
etergent extract of this additional envelope was used to
repare the rabbit hyperimmune serum a-VV-env., which
e tested for its EEV neutralizing capacity. This anti-
erum recognized not only specific EEV proteins but also
MV components, which most probably contaminated the
rude envelope preparation used for immunization (data
ot shown). Therefore, to exclude the possibility that the
ntiserum predominantly neutralized IMV or damaged
EV in the EEV preparation, the monoclonal antibody
B4/2F2 against the 14-kDa IMV protein (Czerny and lahnel, 1990) was included in all in vitro neutralization
xperiments (Ichihashi, 1996; Vanderplasschen et al.,
997). Preimmune serum was used as a negative control
nd as a standard to calculate relative inhibition.
Under these conditions, a-VV-env. antiserum was able
o neutralize freshly prepared EEV in a concentration-
ependent manner (Fig. 1). At a dilution of 1:50, the
ntiserum neutralized 94.5% of the EEV; ;60% inhibition
as observed when the serum was used at 1:1000. The
bservation that EEV can be neutralized by antibodies
tands in sharp contrast to previous reports (Ichihashi,
996; Vanderplasschen et al., 1997).
Production of antisera to individual EEV envelope pro-
eins. Because we had shown that it was possible to
nhibit EEV infection with an antiserum against a mixture
f all envelope proteins, we decided to prepare mono-
pecific antisera against individual envelope proteins
hat might play a role in host cell attachment. We there-
ore expressed the extraviral portions of four likely can-
idates, the proteins encoded by the genes A33R, A34R,
36R, and B5R, as recombinant proteins in heterologous
xpression systems. Each of the recombinant proteins
ontained a terminal 6xHis tag for purification by affinity
hromatography. These tags were added to the opposite
nds with respect to the extremity naturally protruding
ut of the EEV particle, not to interfere with their native
tructure possibly involved in binding to a receptor or
eceptors on host cells. Furthermore, to govern secretion
f the recombinant proteins originating from type II trans-
embrane proteins, a sequence encoding a heterolo-
ous signal peptide was added upstream of the trun-
ated genes (Fig. 2). These strategies allowed recovery
f the extraviral portions of the proteins A33R, A34R, and
5R directly from the supernatant of insect cells infected
ith recombinant baculovirus. However, the expression
FIG. 1. In vitro neutralization of EEV by a-V V-env. antiserum. The
eduction of plaque numbers was calculated relative to control exper-
ments using preimmune serum. Each value represents the mean 6
.E.M. of duplicate measurements from at least four independent
xperiments.evel of protein A34R was fairly low, and protein A36R
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73ANTIBODIES NEUTRALIZING ENVELOPED VACCINIA VIRUSas not expressed at all using the baculovirus system.
hese two proteins were therefore expressed in bacte-
ia, solubilized under denaturing conditions, and rena-
ured during purification (see Materials and Methods).
The different preparations of native EEV envelope pro-
eins were used to immunize rabbits, and the specifici-
ies of the antisera were confirmed by immunoblotting
data not shown). Antibody titers were determined by
LISA on entire EEV particles (Table 1).
In vitro EEV neutralization by antisera to individual
nvelope proteins. The plaque inhibition assay previ-
usly performed with the a-VV-env. antiserum was re-
eated using the antisera against individual envelope
roteins at three different concentrations (Fig. 3). The
nti-B5R protein antiserum neutralized EEV infectivity to
early the same extent as the a-VV-env. antiserum or
ven slightly higher at low concentrations: At a dilution of
:5000, this serum showed 43% inhibition, whereas a-VV-
nv. neutralized EEV to 37% (data not shown). For the
ther antisera, only marginal inhibition levels of up to
0% were observed. This might be due to a sterical
indrance to host cell attachment after antibody coating
f the EEV surface. This hypothesis is in agreement with
he observation that in these cases, the inhibition levels
ere less dependent on antibody concentrations. Inter-
TABLE 1
Rabbit Hyperimmune Sera
Serum Titer
a-A33R 1:2500
a-A34R 1:300
a-A36R 1:80
a-B5R 1:5000
a-V V-env. 1:10,000
Note. The titers were determined by ELISA and represent the serum
ilution resulting in the double of the OD490nm value obtained with
FIG. 2. Production of extraviral portions of EEV envelope proteins.
ote that proteins A33R, A34R, and A36R are type II transmembrane
roteins (see text for details). Amino acid numbering is according to the
orresponding open reading frames in strain WR, and A33R, A34R, and
36R correspond to SalF3R, SalF4R, and SalF6R, respectively.reimmune serum. cstingly, the neutralizing activity of the anti-B5R protein
as slightly increased in combination with either of the
hree other antisera.
The same antisera that neutralized EEV infectivity in
he plaque inhibition assay, that is, a-VV-env. and a-B5R,
lso inhibited comet formation (Fig. 4). The size of the
omets decreased with increasing antibody concentra-
ions, and complete inhibition was obtained at dilutions
f 1:500 and 1:100 for a-VV-env. and a-B5R, respectively.
he anti-A33R protein antiserum also slightly inhibited
omet formation at a dilution of 1:10, whereas a-A34R
nd a-A36R did not show any effect even at such high
oncentrations. It has been shown that inhibition of
omet formation does not exclusively have to be due to
eutralization of the freshly released EEV but that it may
FIG. 3. In vitro neutralization of EEV by antisera to individual EEV
nvelope proteins. Each serum was used at a dilution of 1:500, 1:100,
nd 1:50, shown in the left, middle, and right columns, respectively, of
ach group. The reduction in plaque numbers was calculated relative
o the control with preimmune serum, and a-V V-env. antiserum was
sed as a positive control for inhibition. Each value represents the
ean 6 S.E.M. of duplicate measurements from at least four indepen-
ent experiments.
FIG. 4. Inhibition of comet formation by monospecific antisera. The
ndicated dilution corresponds to the highest dilution that resulted in
omet inhibition. 2, No inhibition of comet formation.
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74 GALMICHE ET AL.e mediated via an inhibition of EEV release by an
gglutination of the EEV on the cell surface (Vander-
lasschen et al., 1997). Nevertheless, it is interesting to
ote that some antibodies did and others did not inhibit
omet formation, and that this characteristic correlated
ith EEV neutralizing activity in plaque inhibition tests.
Relative amounts of envelope proteins in EEV. The
eutralizing activity of an antiserum might simply depend
n the relative abundance of the corresponding protein
n the EEV surface. We therefore estimated the relative
mounts of the four envelope proteins in total EEV lysate
hrough Western blotting using known amounts of the
espective recombinant proteins as standards (Table 2).
5R and A34R represent the most abundant envelope
roteins, whereas the amounts of A33R and A36R pro-
eins were found to be almost an order of magnitude
ower. Because the antiserum against protein A34R did
ot demonstrate any neutralizing activity, a nonspecific
nhibition of EEV infectivity by opsonization with the
-B5R antiserum seemed rather unlikely.
In vivo protection of mice by vaccination with EEV
nvelope proteins. To test whether the neutralizing activ-
ty of specific antisera in vitro correlated with protectivity
n vivo, we vaccinated mice with the same recombinant
roteins. After challenge with lethal doses of vaccinia
irus, 90% of the mice vaccinated with B5R protein were
rotected. Surprisingly, vaccination with A33R protein
TABLE 2
Amounts of Envelope Proteins in EEV
Protein (mg/mg) EEV
A33R ,5
A34R 40
A36R ,10
B5R 30
FIG. 5. Vaccination of mice with EEV envelope proteins. Survival rates
ice after i.n. challenge with 107 pfu at day 0.lso provided protection, resulting in a 100% survival rate
nd in a significantly lower body weight loss and a
ore rapid recovery from infection than with B5R protein
Fig. 5).
Before challenge, a serum sample had been taken
rom each mouse to verify the antibody response to
accination by ELISA and Western blotting (data not
hown). Furthermore, in the case of vaccination with the
33R and B5R proteins, the ELISA serum titers were
ompared with the progression of infection after chal-
enge (Fig. 6). For mice vaccinated with B5R protein, the
uality of protection clearly paralleled the antibody titers
bserved before challenge. Mice with higher antibody
iters recovered faster from infection, whereas the
ouse showing the lowest antibody titer did not survive.
nterestingly, no such association was found in mice
accinated with A33R protein. Because the anti-A33R
ntiserum did not neutralize EEV in vitro, it was possible
hat the protection mediated by A33R protein was not
ue to a humoral but rather to a cellular immune re-
ponse.
Passive protection of mice by transfer of hyperimmune
era to EEV envelope proteins. To test whether the
rotectivity of the B5R and A33R proteins in vivo was
ediated by antibodies, we injected rabbit and mouse
yperimmune sera into mice having been challenged
ith vaccinia virus a few hours earlier. A significant
roportion of mice that received a-B5R antisera sur-
ived the challenge (Fig. 7), confirming our findings
rom the in vitro neutralization and active vaccination
xperiments. Surprisingly, however, best passive pro-
ection was obtained with mouse a-A33R antiserum,
hereas rabbit a-A33R had no protective effect. All the
ouse sera were subsequently tested in in vitro
laque inhibition assays. As for the rabbit sera, only
he mouse a-B5R antiserum was able to inhibit EEV
nfection in vitro (data not shown).
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75ANTIBODIES NEUTRALIZING ENVELOPED VACCINIA VIRUSProtection of mice by DNA vaccination. For technical
easons, two different expression systems had been
sed to produce the four recombinant proteins tested
hroughout this study. Because only mice immunized
ith baculovirus produced proteins had been protected
n the vaccination studies, we had to verify that this result
as not due to the different methods of protein prepara-
ion. DNA vaccination has been proved to offer a pow-
rful alternative to classical vaccination protocols (Has-
ett and Whitton, 1996) and would allow us to compare
he protective effects of the different EEV proteins in a
ore standardized manner. We therefore subcloned the
ull-length genes encoding the four envelope proteins
nto a eukaryotic expression vector. Except for the A33R
onstruct, we were unable to detect expression of the
enes in Western blots using lysates from transiently
FIG. 6. Comparison of antibody titers and protectivity in individual
accinated mice. Serum samples were taken from each mouse vacci-
ated with envelope proteins B5R (A) and A33R (B) before i.n. challenge
ith 107 pfu. The OD490 nm values obtained by ELISA from the sera
rechallenge and the relative body weights of the mice postchallenge
re indicated.ransfected cell lines (data not shown). Nevertheless, we secided to vaccinate mice with these constructs and
ubsequently challenged them with lethal doses of vac-
inia virus. Plasmids encoding the proteins A33R and
5R protected mice against infection (Fig. 8), thus con-
irming the results obtained with protein vaccination. Fifty
ercent of the mice immunized with A36R DNA survived
fter 2 weeks, but in contrast to those immunized with
33R and B5R DNA, they remained sick and did not
egain their normal body weights even after 21 days
data not shown). In this case, cellular immunity might
ave played a role.
DISCUSSION
The two infectious forms of vaccinia virions, IMV and
EV, differ in structure, antigenicity, and various other
iological properties. They use different mechanisms to
nfect host cells, notably by binding to different cell sur-
ace receptors (Vanderplasschen and Smith, 1997). EEV
epresents the biologically relevant form of the virus to
pread infection in vitro and in vivo (Blasco and Moss,
992; Payne, 1980) and seems more selective in terms of
ffinity to different cells and tissues (Vanderplasschen
nd Smith, 1997). Recently, a novel model has been
roposed suggesting that EEV entry consists of binding
o the cell, endocytosis, and disruption of the EEV outer
embrane within the acidic environment of the endo-
ome, releasing IMV that gains access to the cytoplasm
ia the IMV infection mechanism (Ichihashi, 1996;
anderplasschen et al., 1998). Surprisingly, although IMV
nfectivity was readily inhibited by antibodies in vitro, two
roups independently reported unsuccessful attempts to
eutralize EEV using monoclonal antibodies and sera
rom infected animals and vaccinated humans (Ichihashi,
996; Vanderplasschen et al., 1997). Nevertheless, anti-
odies were shown to inhibit EEV release from infected
ells, which explains why these antibodies were able to
revent comet formation (Engelstad et al., 1992; Vander-
lasschen et al., 1997). This inhibition of virus egress
ight also represent one possible mechanism of anti-
ody-mediated immunoprotection against vaccinia virus
nfection in vivo.
In this study, we produced antisera that not only
locked comet formation but also neutralized EEV infec-
ivity in plaque inhibition assays. A rabbit hyperimmune
erum against total EEV envelope lysate neutralized
94% of fresh EEV. An antiserum against recombinant
rotein B5R showed a similar effect, whereas antisera
gainst three other EEV envelope proteins, A33R, A34R,
nd A36R, did not show any significant inhibition. The
5R gene product seems therefore to be a major target
or antibody mediated inhibition of EEV infectivity. It is not
urprising that the monoclonal antibodies used in the
ormer reports did not show any neutralizing effect if they
ere not directed against the B5R protein or against thepecific protective epitope on that protein. However, be-
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76 GALMICHE ET AL.ause B5R is an abundant component of the EEV enve-
ope and elicited high antibody titers after immunization,
t is not clear why the polyclonal antisera used by the
thers did not inhibit plaque formation by EEV. A possible
xplanation for this apparent discrepancy might be that
omehow the protective epitope on the B5R protein is not
mmunogenic during a natural infection or during vacci-
ation using whole virions. This might represent a mech-
nism vaccinia virus has adopted during evolution to
scape a first line of defense by the host’s immune
ystem. In contrast to the other groups, we might have
ypassed this mechanism by presenting to the immune
ystem an enriched fraction of protective B5R epitopes in
he form of solubilized EEV membranes or of purified
ecombinant protein. In both cases, the lower abundance
r the lack of otherwise immunodominant IMV proteins
ight be crucial.
Vaccination with recombinant extraviral domain of the
5R protein or with expression plasmids encoding the
FIG. 7. Passive vaccination of mice with anti-envelope protein antise
f rabbit or mouse antiserum 5 h later. Survival rates and mean value
ymbols), and the m indicates mouse antisera (closed symbols).
FIG. 8. Vaccination of mice with DNA encoding EEV envelope prote
roups of six vaccinated mice after i.n. challenge with 106 pfu.ull-length B5R gene protected mice against a lethal
accinia virus challenge. This protectivity was most likely
ediated by antibodies because mice showing higher
nti-B5R antibody titers developed less severe infection
nd because nonvaccinated mice were passively pro-
ected by injection of anti-B5R hyperimmune sera. The
34R and A36R proteins did not show any protectivity.
owever, due to the poor expression levels of the A34R
nd A36R genes using the baculovirus expression sys-
em, these proteins had been expressed in bacteria and
ubsequently renatured for immunization. We therefore
annot exclude the possibility that authentic A34R and
36R proteins containing the same eukaryotic posttrans-
ational modifications as their natural counterparts in the
iral envelope might confer protection.
Unexpectedly, vaccination with the A33R gene product
lso provided a very efficient immunoprotection that
ould be passively transferred to naive animals. How-
ver, this protectivity did not correspond to specific an-
ups of five mice were i.n. challenged with 105 pfu and received 200 ml
lative body weights are shown. The r indicates rabbit antisera (open
rvival rates and mean values of relative body weights are shown forra. Gro
s of reins. Su
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77ANTIBODIES NEUTRALIZING ENVELOPED VACCINIA VIRUSibody titers, and passive protection was obtained only
ith mouse and not with rabbit hyperimmune sera. To-
ether with the finding that anti-A33R antibodies were
nable to neutralize EEV in vitro, these results suggest
hat those antibodies do not directly interfere with the
nfection mechanism. Instead, it is possible that anti-
33R antibodies disrupt the virus dissemination pathway
n conjunction with some homologous serum component
ike complement by destroying EEV particles or virus-
nfected cells. Alternatively, passive transfer of homolo-
ous effectors of cell-mediated immunity might have
acilitated to build up an efficient cellular response,
hereas their heterologous analogues in the rabbit se-
um did not. The protective mechanism may also involve
c receptors on accessory cells (NK, macrophages),
uch that rabbit antibodies are less effective in mice. In
ny case, of the four envelope proteins tested, protein
5R remains the most likely target for direct antibody
nhibition of infection and thus might play an important
ole in host cell attachment and/or penetration.
Knock-out mutants lacking the B5R gene showed a
mall plaque phenotype and produced a significantly
maller number of EEV due to a failure to wrap IMV
articles, resulting in a greatly attenuated infectivity in
ivo (Engelstad and Smith, 1993; Takahashi-Nishimaki et
l., 1991; Wolffe et al., 1993). The extraviral N-terminal
ortion of the B5R protein contains four short consensus
epeats (SCRs) with homologies to factor H, a compo-
ent of the complement cascade (Engelstad and Smith,
993; Takahashi-Nishimaki et al., 1991). If B5R is involved
n host cell attachment, as may be concluded from the
resent study, one would expect that deletion of portions
f the corresponding extraviral domain would have a
trong effect on EEV infectivity. Interestingly, deletion of
ne to three SCRs resulted in a large increase in the
umber of released EEV that produced small plaques
Mathew et al., 1998), and mutants lacking all four SCRs
roduced normal plaques (Herrera et al., 1998). All these
eletion mutants apparently showed normal EEV infec-
ivities in vitro. At first sight, this observation is difficult to
econcile with our results. One possible explanation
ight be that the short spacer region between SCR 4 and
he transmembrane domain, which had not been deleted
n those constructs, contains the epitope constituting the
arget for our neutralizing antibodies. In this case, the
CRs might provide a natural protection mechanism for
he virus by shielding this sensitive epitope from recog-
ition by cells of the immune system. This would provide
further possible explanation of why our antigen prep-
rations, but not natural infection or vaccination with
hole virus, stimulated the formation of protective anti-
odies. On the other hand, this hidden epitope would
hen be unlikely to play a role in cell attachment but
ight be involved in later events, maybe during penetra-
ion into a host cell. Alternatively, it still cannot be ex-
luded that the anti-B5R antibodies neutralize EEV by Nimply masking another, maybe yet unknown, envelope
omponent involved in host cell attachment. Further
tudies to investigate the role of the B5R envelope pro-
ein in the initial steps of vaccinia virus infection are
nderway.
MATERIALS AND METHODS
Cells and viruses. The rabbit kidney cell line RK13
ATCC 37-CCL), the human osteosarcoma cell line 143B
k2 (ATCC 8303-CRL), and the mouse fibroblastic cells
IH 3T3 (ATCC 1658-CRL) were cultured in Dulbecco’s
odified Eagle’s medium (DMEM). The medium was
upplemented with 10% heat-inactivated (30 min at 56°C)
etal calf serum (FCS) and 100 U/ml and 100 mg/ml
enicillin and streptomycin, respectively. Spodoptera fru-
iperda (Sf9) insect cells (ECACC 89070101) were cul-
ured at 28°C in SF-900 II medium (Life Technologies,
nc.) in the absence of serum as suspension culture in
rlenmeyer flasks shaken at 125 rpm or as monolayer.
Vaccinia virus strain IHD-J was used in this study, and
EV was prepared as described previously (Vander-
lasschen et al., 1997). Briefly, RK13 cells were infected
ith 1 plaque forming unit (pfu)/cell, and the supernatant
as recovered 24 h postinfection. After clarification by
ow-speed centrifugation, the EEV suspension was di-
uted in DMEM containing 2% FCS, and any contaminat-
ng IMV infectivity was neutralized by the addition of
onoclonal antibody 5B4/2F2 (Czerny and Mahnel, 1990)
t a dilution of 1:1000.
Production of the extraviral domains of EEV envelope
roteins. The portions of the genes A33R, A34R, A36R,
nd B5R encoding the extraviral domains of the corre-
ponding proteins were amplified by PCR from genomic
NA of strain IHD-J. The primers used were based on the
equences in strain WR (Smith et al., 1991) and are
resented in Table 3. The resulting fragments were sub-
loned into pBluescript (pBS; Stratagene) via PstI and
indIII sites contained within the primers, and the con-
tructs were sequenced. To govern secretion of the type
I proteins encoding by A33R, A34R, and A36R, a heter-
logous signal sequence originating from the human
ecretory component (Eiffert et al., 1991; Krajci et al.,
991; Rindisbacher et al., 1995) was amplified by PCR
nd fused to the 59 ends of the fragments via SacI and
stI sites contained within the primers, according to the
trategy shown in Fig. 2.
For purification by Ni21-chelate affinity chromatogra-
hy, all recombinant proteins were designed to contain a
erminal 6xHis tag. We wanted to keep the terminal
omains intact corresponding to the protruding extrem-
ties of the envelope protein in vivo. Therefore, for the
ype I protein encoded by the truncated B5R gene, the
xHis tag was added to the C-terminus. For the type II
ecombinant proteins, the 6xHis tag was fused to the
-terminus, 1 amino acid downstream of the cleavage
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78 GALMICHE ET AL.ite of the heterologous signal sequence, as will be
escribed elsewhere (Galmiche et al., unpublished ob-
ervations). The resulting sequences were subcloned
nto pBlueBac4 (InVitrogen) to generate recombinant
aculoviruses for the expression of native proteins. Al-
ernatively, similar constructs without signal sequences
ere inserted into pQE vectors (Qiagen) and expressed
n bacteria. The bacterial products were bound to Ni21
olumns under denaturing conditions, renatured step-
ise with PBS, and eluted under native conditions.
riefly, total bacterial lysates were solubilized with 6 M
uanidine hydrochloride and loaded onto Ni21-NTA-aga-
ose beads (Qiagen), according to the manufacturer’s
ecommendations. The columns were washed with a
inear gradient of 8–0 M urea in 0.1 M phosphate/0.01 M
ris buffer, pH 8. Bound renatured proteins then were
luted with the same buffer containing 200 mM imida-
ole.
Antibodies. Table 1 describes the antisera against
accinia virus proteins used in this study. The rabbit
-VV-env. was obtained from an animal that had been
mmunized subcutaneously four times at 4-week inter-
als with total EEV membrane protein prepared as de-
cribed previously (Payne, 1979). To generate antisera
gainst the recombinant envelope proteins, 100–200 mg
f each native protein was injected five times at 4-week
ntervals. The B5R and A33R gene products were ob-
ained in sufficient amounts from the baculovirus system.
owever, The A36R protein was produced in bacteria
nd renatured as described above, and for the A34R
rotein, a mixture of baculovirus and bacteria protein
as injected. All antisera were produced using Freund’s
omplete and incomplete adjuvant for primary and boost
njections, respectively. The antibodies were stored at
T
Primers Used for PCR Amplificatio
A33R
Protein vaccination 1
DNA vaccination 1
Protein 1 DNA vacc. 2
A34R
Protein vaccination 1
DNA vaccination 1
Protein 1 DNA vacc. 2
A36R
Protein vaccination 1
DNA vaccination 1
Protein 1 DNA vacc. 2
B5R
Protein vaccination 1
2
DNA vaccination 1
2
Note. Sequences corresponding to authentic vaccinia virus protein c
tretch are shown in italics.20°C and heated for 30 min at 56°C before use to rnactivate complement. The titers of the sera were de-
ermined by ELISA on EEV (see below).
Antibody titration. Nunc 96-well plates (Immunoplate
axiSorp) were coated with wildtype EEV (1 mg virus/
ell) in PBS at 4°C overnight. After three washes with
BS, the virus was fixed with 2% formaldehyde for 30 min
t 4°C. After one wash, nonspecific binding sites were
locked with 5% nonfat dry milk in PBS for 1 h at room
emperature. Duplicate samples of antibody dilution se-
ies were then added to the fixed virus and incubated for
h at room temperature. After washing, anti-rabbit IgG
ntibody conjugated with horseradish peroxidase was
dded at a dilution of 1:1000. Using 1,2-phenylene-di-
mine as a substrate, bound antibody was quantified in
n ELISA reader at 490 nm. Each experiment was per-
ormed at least three times. The titer of each antiserum
as defined as the dilution resulting in a signal corre-
ponding to the double of the value obtained with pre-
mmune serum.
Antibody neutralization assay. Fresh EEV (150–200 pfu/
l) in DMEM containing 2% FCS were incubated for 1 h
t 37°C with the specific antisera at variable concentra-
ion or with preimmune serum as a negative control. In
ddition, to neutralize any contaminating IMV or dam-
ged EEV, the monoclonal antibody 5B4/2F2 was added
Vanderplasschen et al., 1997) at a dilution of 1:1000. Of
hese mixtures, 500 ml/well was then directly added to
onfluent 143B tk2 cells in six-well plates and incubated
or 1 h at room temperature. After two washes with PBS,
he cells were incubated for 2 days at 37°C under liquid
verlay, and plaques were counted after staining with
.1% crystal violet.
Comet inhibition assay. RK13 cells grown in six-well
ishes were infected with IMV (50–100 pfu/well) for 1 h at
nvelope Protein Encoding Genes
CCCTGCAGTGCATGTCTGCTAACGAG-39
ATCTAAGATATTATCATGATGACACCAGAA-39
CAAGCTTAGTTCATTGTTTTAACACAAA-39
CCCTGCAGCTGCATTACAAAGAAGAACTG-39
AGAATTCCATTAATAAATGAAATCGCTTAAT-39
CAAGCTTACTTGTAGAATTTTTTAACACATA-39
CCCTGCAGAGGAAAAAGATACGTACTGTC-39
ATCTAGATCAGAAATGATGCTGGTACC-39
CAAGCTTACACCAATGATACGACCGA-39
CCCTGCAGATGAAAACGATTTCCGTTGTTA-39
CAAGCTTA(ATG)6TTCTAACGATTCTATTTCTTGTT-39
ACTCGAGTAAAAATGAAAACGATTTCCGTT-39
CGGTACCTTACGGTAGCAATTTATGGAA-39
egions are indicated in bold. The codons complementary to the 6xHisABLE 3
n of E
59-GC
59-GA
59-GA
59-GC
59-CG
59-GA
59-GC
59-CG
39-GA
59-GC
59-GA
59-CG
59-CA
oding room temperature. After washing, the cells were overlaid
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79ANTIBODIES NEUTRALIZING ENVELOPED VACCINIA VIRUSith 1 ml of DMEM containing 2% FCS and varying
oncentrations of specific antisera or preimmune serum
s a control. The cells were incubated for 2 days at 37°C
nd then stained with crystal violet.
Immunoblotting. Total EEV proteins and purified re-
ombinant EEV envelope proteins were fractionated on
0% or 15% SDS–polyacrylamide gels and subjected to
mmunoblotting. The membranes were incubated with
abbit anti-A33R, anti-A34R, anti-A36R, or anti-B5R anti-
erum at a 1:1000 dilution in TBS-Tween for 1 h at room
emperature. Bound antibody was detected using an
nti-rabbit IgG antibody coupled to horseradish peroxi-
ase and the enhanced chemiluminescence kit from
mersham. EEV envelope proteins were quantified by
ensitometric scanning of individual signals (Elscript
00; ATH Hirschmann, Germany) and by comparison with
he densities of the corresponding bands obtained with
nown quantities of the purified proteins.
Protection of mice by vaccination with individual enve-
ope proteins. Six-week-old female BALB/c mice were
mmunized subcutaneously four times at 2-week inter-
als with the different recombinant EEV membrane pro-
eins (10 mg/injection) emulsified in Freund’s complete
nd incomplete adjuvant for primary and boost injec-
ions, respectively. The mice were then challenged intra-
asally (i.n.) with 107 pfu in 20 ml of PBS, with the animals
nder deep anesthesia. Their body weights were moni-
ored daily, and animals that had lost .30% were killed.
he amount of specific antibody contained in a blood
ample taken before challenge was determined by
LISA (see above).
Protection of mice by passive transfer of hyperimmune
era. Six-week-old naive mice were anesthetized and
nfected i.n. with 105 pfu in 20 ml of PBS. Five hours after
hallenge, they received intraperitoneally (i.p.) 200 ml of
ouse or rabbit hyperimmune serum against individual
ecombinant envelope proteins. Infection was monitored
ia the body weight of the animals as described above.
Protection of mice by DNA vaccination. The complete
pen reading frames A33R, A34R, A36R, and B5R from
train IHD-J were amplified by PCR using primers con-
aining unique restriction sites (Table 3) and inserted into
he eukaryotic expression vector pCI (Promega). Six-
eek-old female BALB/c mice were immunized by four
ntramuscular injections without adjuvant at 2-week in-
ervals with these constructs or with empty vector as a
ontrol (100 mg in 100 ml of PBS/injection). The mice
ere then challenged i.n. with 106 pfu in 20 ml of PBS,
ith the animals under deep anesthesia. Infection was
onitored via the body weight of the animals as de-
cribed above.
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